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Purpose: There are many similarities in the clinical presentation of Leber hereditary optic neuropathy (LHON) and in
patients who have optic neuropathy and a history of heavy tobacco and alcohol consumption. The main objective of this
study is to investigate the frequency of primary and secondary mitochondrial DNA (mtDNA) mutations for LHON in
patients diagnosed as having alcohol and tobacco optic neuropathy (ATON).
Methods: Twenty-six patients who had a history of heavy alcohol and tobacco consumption and who developed bilateral
optic neuropathy were tested for primary mutations (G11778A, T14484C, and G3460A) by restriction analysis, and 14
secondary mutations in the genes mitochondrially encoded NADH dehydrogenase 1 (MT-ND1), mitochondrially encoded
NADH dehydrogenase 4 (MT-ND4), mitochondrially encoded NADH dehydrogenase 4L (MT-ND4L), mitochondrially
encoded  NADH  dehydrogenase  5  (MT-ND5),  mitochondrially  encoded  NADH  dehydrogenase  6  (MT-ND6),  and
mitochondrially encoded cytochrome B (MT-CYB) by direct sequencing.
Results: Four (15.4%) of 26 patients tested positive for LHON primary mutations, two for the G11778A mutation, and
two for the T14484C mutation. No patient tested positive for any of the 14 secondary mutations. Familial recurrence was
present in four patients, and only three of these patients have presented the LHON mutation.
Conclusions: The diagnosis of LHON should be considered in all patients diagnosed as having optic neuropathy,
particularly those with familial recurrence of vision loss.
Leber  hereditary  optic  neuropathy  (LHON)  is  a
maternally inherited mitochondrial disease characterized by a
bilateral acute or subacute painless loss of vision, central or
cecocentral scotoma, and dyschromatopsia [1].
Most LHON patients have a profound decrease of visual
acuity of less than 20/200 to counting fingers range and visual
loss occurs simultaneous in both eyes or in one eye initially,
which is followed by visual loss in the other eye within weeks
to months [2,3]. LHON usually affects healthy young male
adults in the second and third decades of life, with a mean age
at onset of 22 years [4], ranging from 5 to 81 years [5,6].
Seventeen  mutations  related  to  LHON  have  so  far  been
studied, G11778A, G3460A, and T14484C account for 95%
of  cases  (primary  mutations);  the  other  14  mutations  are
secondary  mutations  (T4160C,  C4171A,  G11696A,
T11253C,  T10663C,  A13637G,  G13730A,  G14459A,
C14482G,  A14495G,  T14898C,  C14568T,  G14596A,
G15257A) [7-9]. Three mitochondrial DNA (mtDNA) point
mutations, at positions 11778/ND4, 3460/ND1, and 144484/
ND6, are primary mutations responsible for the large majority
of cases reported [2,4]. These three point mutations are located
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in the genes of nicotinamide adenine dinucleotide hydride
(NADH)  dehydrogenase  subunits  of  complex  1  of  the
respiratory chain. These mutations may either decrease the
ATP synthesis for a cell or induce a chronic overproduction
of reactive oxygen species in the mitochondria. The resultant
oxidative stress may trigger apoptosis in the cell [3]. The
degeneration of the optic nerve is due to a loss of retinal
ganglion cells and optic nerve axons, with a preferential loss
of p-ganglion cells, which are responsible for central vision
[4]. LHON has an incomplete penetrance, and chances for
carriers  of  a  LHON  mutation  to  become  affected  are
approximately 30% to 50% for male subjects and 10% to 15%
for female subjects. The mutation in the mtDNA is essential
but it alone is not enough to initiate the disease. Secondary
genetic and/or epigenetic or environmental risk factors might
play a role in the pathogenesis. Nonhereditary causes, such as
smoking, alcohol, drug use, trauma, or vascular causes, have
been postulated as risk factors for the phenotypic expression
of LHON [4,10].
The optic neuropathy in patients with heavy tobacco–
alcohol consumption is characterized by subacute painless
loss of visual acuity and centrocecal scotomas occurring most
frequently in men with heavy tobacco use, alcohol use, or both
[11,12].  There  are  many  similarities  in  the  clinical
presentation  of  LHON  and  in  patients  who  have  optic
neuropathy  and  a  history  of  heavy  tobacco  and  alcohol
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3175consumption. The pathogenesis of the disease is supposed to
be secondary to a nutritional deficiency or the direct toxic
effect of alcohol, tobacco, or both. The cause of alcohol and
tobacco optic neuropathy (ATON) has not yet been proven;
however an underlying susceptibility that predisposes patients
to this condition has been postulated [12]. Since there are
many similarities in the clinical presentation of LHON and
ATON, the investigation of molecular genetic LHON mtDNA
mutations is essential for the differential diagnosis between
these two neuropathies [12].
METHODS
Patients:  Between  August  2007  to  November  2009,  26
patients  from  the  Departamento  de  Oftalmologia  da
Faculdade de Ciências Médicas - Universidade Estadual de
Campinas (UNICAMP, Campinas, São Paulo, Brazil) were
examined. Informed consent was obtained from participants
before the study, conforming to the tenets of the Declaration
of Helsinki and following the Guidance for Sample Collection
of  Human  Genetic  Disease  (National  863-Plan)  by  the
Research Ethics Committee/Faculdade de Ciências Médicas
- Universidade Estadual de Campinas, UNICAMP (number:
690/2004).  The  inclusion  criteria  were:  history  of  heavy
tobacco and alcohol consumption (100 ml of distilled alcohol
per day during 1 year or more) in patients older than 18 years,
(sub)  acute  visual  loss  (less  than  20/40),  and  central  or
cecocentral scotomas. Patients with ocular surgery or any
other pathology that could cause visual loss were excluded as
were  those  with  metabolic  disease  (diabetes  mellitus).
Computerized tomography or magnetic resonance of the brain
was used to detect any other neurologic condition.
Methods: Complete eye examinations were performed, and
peripheral blood samples (5 ml, blood drawn by venipuncture)
were  collected  in  EDTA  vacutainers  (Greiner  Bio-one
Catalogue no. 455036; Frickenhausen, Germany). The sample
was sent at 4 °C to the laboratory of Centro de Biologia
Molecular e Engenharia Genética (CBMEG) - UNICAMP for
mtDNA analysis.
Genomic DNA was extracted from venous blood samples
using  standard  phenol–chloroform  extraction.  Molecular
genetic analysis was performed using PCR amplification of
DNA extracted from peripheral blood leucocytes [13]. The
presence of the G3460A, G11778A, and T14484C mutations
was  examined  by  PCR-Polymerase  Chain  Reaction  -
Restriction  fragment  length  polymorphism  (RFLP)  with
restriction endonuclease digestions. The secondary mutations
in genes mitochondrially encoded NADH dehydrogenase 1
(MT-ND1), mitochondrially encoded NADH dehydrogenase
4  (MT-ND4),  mitochondrially  encoded  NADH
dehydrogenase  4L  (MT-ND4L),  mitochondrially  encoded
NADH  dehydrogenase  5  (MT-ND5),  mitochondrially
encoded  NADH  dehydrogenase  6  (MT-ND6),  and
mitochondrially  encoded  cytochrome  B  (MT-CYB)  were
screened by direct sequencing using an ABI prism Big Dye
Terminator cycle sequencing Ready Reaction kit V 3.1 (ABI
Prism/ Apllied Biosystems, Foster City, CA) and analyzed on
an ABI Prism 3100 Genetic Analyzer (Applied Biosystem).
All sequences were analyzed against mitochondrial reference
sequence NC_012920.
RESULTS
Twenty-five (96.2%) male patients and one female patient
(3.8%) were tested (Table 1). The mean age at onset was 38
years, ranging from 17 to 52 years. All 26 (100%) patients had
a history of heavy alcohol consumption and 25 (96.2%) had a
history of tobacco abuse, at least 1 year before the patients had
manifested the loss of vision and optic neuropathy. Visual
acuity  ranged  from  20/50  to  counting  finger  at  1  m.  All
patients  showed  scotomas  in  the  visual  field  in  static
perimetry,  two  patients  (7.7%)  showed  relative  central
scotoma,  and  24  patients  (92.3%)  showed  central  or
ceccocentral scotomas. When Ishihara’s test was performed,
all patients showed abnormal results. Four (15.4%) of 26
patients tested positive for LHON primary mutations, two for
the G11778A mutation, and two for the T14484C mutation.
Three of the four mutant homoplasmic patients (4, 8, and 15)
had a maternal antecedent of visual loss. These patients were
not related. None of the 26 patients tested positive for any of
the 14 secondary mutations analyzed.
DISCUSSION
It  is  known  that  several  primary  inherited  disorders  of
mitochondrial dysfunction target the optic nerve, including
LHON.  In  addition,  disorders  of  secondary  mitochondrial
dysfunction  also  target  the  optic  nerve.  These  include
dominant optic atrophy, ATON, and chloramphenicol optic
neuropathy [14,15].
Mitochondrial energy production decreases with age, and
the timing of visual loss in patients at risk for LHON may
reflect  the  threshold  at  which  the  already  reduced
mitochondrial function deteriorates to a critical level [16].
The possibility that environmental factors, both internal
and external, could trigger vision loss in susceptible patients
with LHON has been based on the hypothesis that vision loss
is  linked  to  defects  in  oxidative  phosphorylation  [14].
Systemic  illnesses,  immunologic  factors,  nutritional
deficiencies,  medications,  or  toxins  that  stress  or  directly
inhibit mitochondrial metabolism could conceivably initiate
or increase phenotypic manifestation of the disorder. Despite
the  great  advances  in  our  understanding  of  mitochondrial
genetics and disease over the past decade, the underlying
pathophysiological  mechanisms  linking  the  specific  gene
defect with the clinical manifestation of LHON remain elusive
[16].
ATON and LHON have similar clinical characteristics
and the pathogenesis of the visual loss in the two diseases may
be related. Patients who have LHON may be misdiagnosed as
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3176TABLE 1. SUMMARY OF CLINICAL AND MOLECULAR DATA OF THE PATIENTS STUDIED.
Patient/gender Age of
manifestation
Visual acuity Visual fields Familial
recurrence
Mutation
1/M 35 OD 20/200 Cecocentral - -
    OS 20/200 Cecocentral    
2/M 35 OD 20/100 Central - -
    OS 20/50 Central    
3/M 35 OD 20/100 Central - -
    OS cf at 1m Central    
4/M 47 OD 20/200 Cecocentral + T14484C
    OS 20/200 Cecocentral    
5/M 46 OD 20/50 Relative central scotoma - -
    OS 20/60 Relative central scotoma    
6/M 42 OD 20/200 Cecocentral - -
    OS 20/200 Cecocentral    
7/M 52 OD 20/200 Central - -
    OS 20/100 Central    
8/M 35 OD cf at 1m Fovea 4dB + G11778A
    OS cf at 1m Fovea 0dB    
9/M 46 OD 20/100 Central - -
    OS 20/100 Central    
10/M 38 OD 20/100 Central - -
    OS 20/100 Central    
11/M 43 OD cf at 1m Central - -
    OS cf at 1m Central    
12/M 44 OD 20/50 Relative central scotoma - -
    OS 20/50 Relative central scotoma    
13/M 41 OD 20/200 Fovea 9dB - -
    OS 20/200 Fovea 13dB    
14/M 52 OD cf at 1m Cecocentral - -
    OS cf at 1m Cecocentral    
15/M 27 OD cf at 1m Central + T14484C
    OS cf at 1m Central    
16/M 40 OD 20/50 Central - -
    OS 20/50 Central    
17/M 50 OD cf at 1m Fovea 5dB - -
    OS 20/200 Fovea 0dB    
18/M 44 OD cf at 1m Fovea 10dB - -
    OS cf at 1m Fovea 10dB    
19/M 17 OD 20/100 Central + -
    OS 20/200 Central    
20/M 41 OD 20/200 Central - -
    OS 20/50 Central    
21/M 29 OD 20/50 Central - -
    OS 20/50 Central    
22/M 40 OD 20/60 Central - -
    OS 20/100 Cecocentral    
23/M 33 OD 20/100 Central - -
    OS 20/100 Central    
24/M 38 OD 20/60 Central - -
    OS 20/60 Central    
25/M 17 OD cf at 1m Fovea 0dB - G11778A
    OS cf at 1m Cecocentral    
26/F 20 OD 20/50 Central - -
    OS 20/100 Cecocentral    
        Abbreviations: OD represents oculus dexter, right eye; OS represents oculus sinister, left eye; Cf represents counting finger (it
        is a range, a measurment of visual acuity); dB represents decibel.
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the clinical expression of a disease that otherwise would go
unnoticed.
It has been noted that although a substantial percentage
of the population uses alcohol, relatively few persons develop
visual  loss.  Conversely,  some  patients  who  consume
relatively small amounts of alcohol develop a bilateral optic
neuropathy thought to be caused by the toxic effects of alcohol
[12].  Many  authors  have  studied  the  correlation  between
abusive use of tobacco and alcohol and the visual loss in
mutant patients for LHON [12,17]. A recent multicenter study
identified an association between smoking and visual loss, and
this relationship might even be dose responsive. The authors
also  identified  an  increased  visual  failure  with  alcohol
consumption but only with heavy intake of alcohol [18].
In our study, 26 patients who had a history of heavy
alcohol  consumption  and  developed  bilateral  optic
neuropathy were tested for the three primary (G117778A,
T14484C, and G3460A) and 14 secondary LHON mtDNA
mutations. The genetic molecular analysis tested positive for
LHON in four patients, two patients tested positive for the
G11778A  mutation,  and  two  patients  tested  positive  for
T14484C mutations. Three of these patients had a family
history  of  vision  loss  in  maternal  relatives,  and  the  other
patient had no information about his relatives. The absence of
secondary  mutations  in  our  study  is  concordant  with  the
literature because these mutations are responsible for less than
5% of the cases of LHON [7,9]. Our first hypothesis was not
LHON  for  these  four  mutant  patients  because  they  had
atypical  clinical  presentation.  Three  of  the  patients  had
subacute visual loss during a period of 6 months to 2 years.
The fourth patient lost his vision at 17 years but started to drink
and smoke when he was 14 years old.
Despite  all  patients  having  had  heavy  alcohol
consumption during at least 1 year and optic neuropathy, the
mutations for LHON were detected only in patients with a
maternal antecedent of visual loss.
In this study we cannot make any definitive statement
between alcohol and LHON manifestation. Otherwise, only
patients with a family history showed the mutation for LHON.
We could suggest that epigenetic factors, more so than
environmental  risk  factors,  would  be  determinants  in  the
phenotypic expression of LHON, such as the co-existence of
homoplasmic  mutation,  the  presence  of  nuclear-encoded
factors, and an X-linked modifier locus [16]. The underlying
mtDNA  haplotype  may  also  influence  the  presence,
penetrance, or expression of a mtDNA point mutation and
disease severity [4,16].
New studies will be necessary to better understand the
importance of genetic, epigenetic, and environmental factors
in LHON expression. There are no studies at the moment
clearly  confirming  the  influence  of  smoking  and  heavy
alcohol  consumption  in  the  expression  of  visual  loss  in
mitochondrial optic neuropathy. Alcohol and tobacco may
trigger  visual  loss  by  other  mechanisms  besides  mtDNA
mutation for LHON, and this is possibly related to epigenetic
factors.
The present study highlights the importance of careful
anamnesis focusing on familial recurrence of visual loss in
patients with optic neuropathy to indicate molecular genetic
analysis.  Genetic  counseling  of  families  with  LHON
mutations  and  advice  on  smoking  avoidance  and  alcohol
intake are important to prevent visual loss.
ACKNOWLEDGMENTS
This study was approved by the ethics committee: Comitê de
Ética  em  Pesquisa/  Faculdade  de  Ciências  Médicas/
Universidade  Estadual  de  Campinas  (number:  690/2004).
This  work  was  supported  by  the  Fundação  de  Amparo  a
Pesquisa do Estado de São Paulo (FAPESP). The authors
thank FAPESP for supporting this study.
REFERENCES
1. Maciel-Guerra  AT,  Zanchetta  LM,  Amaral  Fernandes  MS,
Andrade PB, do Amor Divino Miranda PM, Sartorato EL.
Leber’s hereditary optic neuropathy: clinical and molecular
profile  of  a  Brazilian  sample.  Ophthalmic  Genet  2010;
31:126-8. [PMID: 20565249]
2. Sadun F, De Negri AM, Carelli V, Salomao SR, Berezovsky A,
Andrade R, Moraes M, Passos A, Belfort R, Rosa AB, Quiros
P, Sadun AA. Ophthalmologic findings in a large pedigree of
11778/Haplogroup J Leber hereditary optic neuropathy. Am
J Ophthalmol 2004; 137:271-7. [PMID: 14962416]
3. Quiros PA, Torres RJ, Salomao S, Berezovsky A, Carelli V,
Sherman J, Sadun F, De Negri A, Belfort R, Sadun AA.
Colour vision defects in asymptomatic carriers of the Leber’s
hereditary optic neuropathy (LHON) mtDNA 11778 mutation
from a large Brazilian LHON pedigree: a case-control study.
Br J Ophthalmol 2006; 90:150-3. [PMID: 16424523]
4. Spruijt L, Kolbach DN, de Coo RF, Plomp AS, Bauer NJ,
Smeets HJ, de Die-Smulders CE. Influence of mutation type
on clinical expression of Leber hereditary optic neuropathy.
Am J Ophthalmol 2006; 141:676-82. [PMID: 16564802]
5. Dagi  LR,  Rizzo  JF.  3,  Cestari  DM.  Leber  hereditary  optic
neuropathy  in  an  octogenarian.  J  Neuroophthalmol  2008;
28:156. [PMID: 18562851]
6. Decanini-Mancera A, Harrison AR, Lee MS. Another case of
Leber  hereditary  optic  neurophaty  in  an  octogenarian.  J
Neuroophthalmol 2009; 29:159-60. [PMID: 19491649]
7. Man PY, Turnbull DM, Chinnery PF. Leber hereditary optic
neuropathy. J Med Genet 2002; 39:162-9. [PMID: 11897814]
8. Mroczek-Tonska  K,  Kisiel  B,  Piechota  J,  Bartnik  E.  Leber
hereditary  optic  neuropathy–a  disease  with  a  known
molecular basis but a mysterious mechanism of pathology. J
Appl Genet 2003; 44:529-38. [PMID: 14617834]
9. Yu-Wai-Man  P,  Griffiths  PG,  Hudson  G,  Chinnery  PF.
Inherited  mitochondrial  optic  neuropathies.  J  Med  Genet
2009; 46:145-58. [PMID: 19001017]
10. Tharaphan  P,  Chuenkongkaew  WL,  Luangtrakool  K,
Sanpachudayan T, Suktitipat B, Suphavilai R, Srisawat C,
Sura T, Lertrit P. Mitochondrial DNA haplogroup distribution
Molecular Vision 2011; 17:3175-3179 <http://www.molvis.org/molvis/v17/a342> © 2011 Molecular Vision
3178in pedigrees of Southeast Asian G11778A Leber hereditary
optic  neuropathy.  J  Neuroophthalmol  2006;  26:264-7.
[PMID: 17204919]
11. Borruat  FX,  Hirt  L,  Regli  F.  Optic  neuropathy  caused  by
alcoholism and smoking: a diagnostic pitfall of Leber's optic
neuropathy. Rev Neurol (Paris) 1994; 150:799-801. [PMID:
7597375]
12. Cullom  ME,  Heher  KL,  Miller  NR,  Savino  PJ,  Johns  DR.
Leber’s  hereditary  optic  neuropathy  masquerading  as
tobacco-alcohol  amblyopia.  Arch  Ophthalmol  1993;
111:1482-5. [PMID: 8240101]PubMed
13. Sambrook  J,  Fritsch  EF,  Maniatus  T.  Molecular  cloning:  a
laboratory  manual,  second  ed.,  Cold  Spring  Harbour
Labortory Press, 1989.
14. Carelli  V,  Ross-Cisneros  FN,  Sadun  AA.  Optic  nerve
degeneration  and  mitochondrial  dysfunction:  genetic  and
acquired  optic  neuropathies.  Neurochem  Int  2002;
40:573-84. [PMID: 11850115]
15. Barron MJ, Griffiths P, Turnbull DM, Bates D, Nichols P. The
distributions of mitochondria and sodium channels reflect the
specific energy requirements and conduction properties of the
human optic nerve head. Br J Ophthalmol 2004; 88:286-90.
[PMID: 14736793]
16. Newman NJ. From genotype to phenotype in Leber hereditary
optic  neuropathy:  still  more  questions  than  answers.  J
Neuroophthalmol 2002; 22:257-61. [PMID: 12464728]
17. Kerrison JB, Miller NR, Hsu FC, Beaty TH, Maumenee IH,
Smith KH, Savino PJ, Stone EM, Newman NJ. A case-control
study of tobacco and alcohol consumption in Leber hereditary
optic  neuropathy.  Am  J  Ophthalmol  2000;  130:803-12.
[PMID: 11124301]
18. Kirkman  MA,  Yu-Wai-Man  P,  Korsten  A,  Leonhardt  M,
Dimitriadis K, De Coo IF, Klopstock T, Chinnery PF. Gene-
environment  interactions  in  Leber  hereditary  optic
neuropathy. Brain 2009; 132:2317-26. [PMID: 19525327]
Molecular Vision 2011; 17:3175-3179 <http://www.molvis.org/molvis/v17/a342> © 2011 Molecular Vision
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China.
The print version of this article was created on 4 December 2011. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
3179